Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05419349
  4. Details
NCT05419349 Clinical Trial

Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

Adenocarcinoma of the Esophagogastric Junction Clinical Trial

Official title:
Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05419349
Other study ID # SEEREGJ-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2022
Est. completion date June 7, 2022

Study information
Verified date June 2022
Source Fujian Medical University Union Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study have two aims, the first is to explore the optimal cutoff of TLN for Siewert type II AEG using the Surveillance, Epidemiology, and End Results (SEER) database the second is to provide a more accurate staging for Siewert type II AEG patients.

Recruitment information / eligibility
Status Completed
Enrollment 1819
Est. completion date June 7, 2022
Est. primary completion date June 7, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Siewert type for adenocarcinoma of the esophagogastric junction; pathologically confirmed T1-4aN0-3M0 stage after surgery after a pathological examination of the LNs.

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• esophagogastric junction cancer surgery
esophagogastric junction cancer surgery

Locations
Country Name City State
China Fujian Medical University Union Hospital Fuzhou Fujian

Sponsors (1)
Lead Sponsor Collaborator
Fujian Medical University Union Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Overall survival the time from disease diagnosis to death from any cause 5-year overall survival
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04062656 - Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Phase 2
Active, not recruiting NCT02509286 - Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Phase 3
Completed NCT00849615 - Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Phase 2
Completed NCT02287129 - Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction Phase 2
Recruiting NCT03647540 - The Application of Fluorescence Laparoscopy in the Treatment of Adenocarcinoma of the Esophagogastric Junction N/A
Completed NCT00737373 - Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer Phase 2